According to the “(CDC) Center of Disease Control heart disease is the number one leading cause of death in america. If you have heart disease then you have a higher chance of cardiac arrest or a heart attack.”
The flow of blood through the heart is controlled by four valves. If any are not working correctly, blood cannot flow or be pumped effectively to the heart. The four valves are: the tricuspid, pulmonary semilunar, mitral, and aortic semilunar. There are many abnormalities or defects that can affect their operation and in this paper, I will discuss the most common one which is a “mitral valve prolapse.” A valvular prolapse is an abnormal protrusion of a heart valve that causes the valve to not close completely. It is also known as “click murmur syndrome” and “Barlow’s syndrome” and is more prevalent in women than men. It has a strong hereditary
Heart disease is the number on killer in the United States. Nearly 787,000 people in the U.S. died from heart disease, stroke and other cardiovascular diseases in 2011. That’s about one of every three deaths in America. About 2,150 Americans die each day from these diseases.
The four valves of the heart are the tricuspid valve, the pulmonic valve, the mitral valve, and the aortic valve. The tricuspid valve is located between the right atrium and the right ventricle. It is responsible for allowing blood to flow from the atrium to the ventricle, preventing backflow of blood into the atrium. The pulmonic valve is located between the pulmonary arteries and the right ventricle and is responsible for allowing blood flow from the heart to the lungs. The mitral valve is found between the left atrium and the left ventricle, which allow blood to flow from the left atrium into the left ventricle preventing backflow of blood back into the left atrium. The aortic valve is found between the aorta and the left ventricle and allows blood to flow to the aorta and throughout the body.
The mitral valve is located on the left side of the heart between the left atrium and left ventricle. The purpose of the mitral valve is to form a seal between these two chambers of the heart to prevent the back flow of blood. When blood enters the left side of the heart, it is oxygenated and enters through the pulmonary veins. The blood then travels through the left atrium; the bicuspid (mitral) valve then opens to let the blood flow down to the left ventricle. The left ventricle contracts, causing the mitral valve to close (preventing the backflow of blood).When the left ventricle contracts it is pumping the blood out to the remainder of the body. (Jenkins, 2007)
Although Mitral Valve Prolapse has existed for many years, there are a few facts a person should know while being diagnosed with this disease. Mitral Valve Prolapse is the most common valve abnormality in the U.S (Gillinov 517). About two to three percent of the population has Mitral Valve Prolapse (Gillinov 517). Of that percentage, very few need surgery due to a severe leak (Gillinov 326). If surgical treatment is necessary, a person receiving a non-surgical valve can most likely receive a 20 percent greater chance to live at least 1 year after treatment, compared to patients receiving medication alone (Gillinov 517). This means many people who were born or diagnosed with a valve problem can most likely be diagnosed with Mitral Valve Prolapse over any other heart valve disease. When a father or a mother has Mitral Valve Prolapse, this creates a very high chance when they have a child, the child will be born having
Mitral Valve Prolapse (MVP) is also knows as Barlow’s Syndrome or Click Murmur Syndrome and it affects about 2-6% of the United States population. While Mitral Valve Prolapse is one of the most common heart valve abnormality that can develop in any person at any age. It is usually not life-threatening and the patient might not even have symptoms. A patient might feel symptoms such as Fatigue, chest pain, or palpitations, which will cause a doctor to run tests such as an echocardiogram; causing a detection and confirmation of the Mitral valve prolapse. The MVP abnormality is caused when one or both of the mitral valve flaps are enlarged or have extra tissue. Causing the valve leaflets to not close correctly and allow leakage of blood back into
Heart disease is the leading killer in the United State. One in four deaths of both men and women is due to heart disease, according to the Centers for Disease Control and Prevention.
The main source of death for both men and ladies in the US, coronary illness kills around 1 million Americans every year. The most widely recognized type of coronary illness is coronary supply route sickness (CAD), which can prompt to a heart assault.
Located in between the left atrium and the left ventricle is the bicuspid or better known as the mitral valve. The mitral valve works to prevent the back-flow of blood into the left atrium once it enters the left ventricle. This action may become hindered when the mitral valve prolapses or in other words the valve becomes “floppy” and is no longer strong or tough enough to handle the normal stresses brought upon it. This condition is known as Mitral Valve Prolapse (MVP). It is said to be one of the most common cardiac abnormalities in the general population, effecting 2-3%, approximately 7.8 million people in the United States and over 176 million people worldwide.
1. The possible signs and symptoms of mitral valve dysfunction are fatigue, chest pain, palpitation, dyspnea, tachycardia, anxiety, and migraine headache (Goodman & Snyder, 2013). The most common triad of symptoms associated with mitral valve dysfunction includes rapid and irregular heartbeat, shortness of breath, and fatigue occurs due to dysfunction of the autonomic nervous system. Some patients also feel syncope and numbness or tingling in the hands and feet in case of mitral valve dysfunction (webmd.com, 2016). Therefore, while treating the therapist should be alert for
The study population comprised of 135 symptomatic adult patients (aged 18 to 62 years) of severe rheumatic mitral stenosis, with or without associated mitral regurgitation. Patients with concomitant moderate to severe aortic valve disease were excluded from the study. Among the 135 study patients, 45 had evidence of severe calcification of the mitral valve (Wilkins calcium score 3 or 4), 45 had mild to moderate calcification (Wilkins calcium score 1 or 2) and 45 had no evidence of calcification (Wilkins calcium score 0). A group of 45 healthy subjects served as control. Patients with chronic liver or kidney disease (serum creatinine level >1.5 mg/dl),endocrine disorders affecting calcium metabolism
Aortic stenosis (AS) is one of the most common valvular heart diseases in developing countries, with a prevalence of 3.4%.1 Without surgical intervention, historical mortality rates approach 50% at 2 years after symptoms appear.2 Since its first use in humans by Cribier 15 years ago, transcatheter aortic valve replacement (TAVR) has rapidly become the standard of care for patients with severe, symptomatic aortic stenosis. 3 The PARTNER trial was a revolutionary study starting in 2007 which sought to compare TAVR to the medical management, then the standard of care. 4-6 Leon & Smith spearheaded the group who randomized 1,057 patients with severe aortic stenosis into two groups. 699 patients who were high risk for open surgery (>15%